A new generation of GAL-9-specific inhibitors.

新一代 GAL-9 特异性抑制剂。

• 批准号: 449399
• 负责人: Dumoulin Alyssa
• 金额: $ 1.27万
• 依托单位: INRS - (Qubec, QC)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-12-01 至 2021-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449399&lang=en
• 关键词: Cancer; Galectines; Glycobiologie; Immunologie; Inhibiteurs; Lectins; Nanoanticorps; Pharmacologie; Technologies De Recherche

Given the critical role of galectins in many diseases and their immunosuppressive functions that antagonize the success of cancer immunotherapy, considerable efforts have been directed towards the development of galectin inhibitors. Building on our recent

鉴于半乳糖凝集素在许多疾病中的关键作用及其拮抗癌症免疫疗法成功的免疫抑制功能，已经针对半乳糖凝集素抑制剂的开发进行了相当大的努力。基于我们最近